{"blog": [], "keywords": [{"value": "Alzheimer's Disease", "name": "subject", "rank": "1", "is_major": "Y"}, {"value": "Decisions and Verdicts", "name": "subject", "rank": "11", "is_major": "N"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "2", "is_major": "Y"}, {"value": "Actavis PLC", "name": "organizations", "rank": "3", "is_major": "Y"}, {"value": "New York State", "name": "glocations", "rank": "4", "is_major": "Y"}, {"value": "Antitrust Laws and Competition Issues", "name": "subject", "rank": "5", "is_major": "N"}, {"value": "Suits and Litigation (Civil)", "name": "subject", "rank": "6", "is_major": "N"}, {"value": "Sweet, Robert W", "name": "persons", "rank": "9", "is_major": "N"}, {"value": "Schneiderman, Eric T", "name": "persons", "rank": "10", "is_major": "N"}], "web_url": "http://www.nytimes.com/2015/05/23/business/court-bars-removal-of-cheaper-alzheimers-drug.html", "document_type": "article", "byline": {"person": [], "original": "By REUTERS", "contributor": "", "organization": "REUTERS"}, "type_of_material": "Brief", "multimedia": [], "section_name": "Business Day", "word_count": "157", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "A federal appeals court in New York ruled on Friday that Actavis cannot withdraw its top-selling Alzheimer\u2019s disease drug from the market in favor of a more expensive extended-release version.", "pub_date": "2015-05-23T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "Court Bars Removal of Cheaper Alzheimer&#8217;s Drug ", "main": "Court Bars Removal of Cheaper Alzheimer&#8217;s Drug ", "content_kicker": "Business Briefing"}, "print_page": "2", "snippet": "A federal appeals court in New York ruled on Friday that Actavis cannot withdraw its top-selling Alzheimer\u2019s disease drug from the market in favor of a more expensive extended-release version.", "_id": "555fba6a38f0d80e70a9bbb4", "slideshow_credits": null, "abstract": "Federal appeals court in New York upholds previous court order that blocked Actavis from taking Alzheimer's drug Namenda IR off market and replacing it with a more expensive extended-release version; New York Atty Gen Eric T Schneiderman had sued to block switch."}